中国学术期刊网络出版总库入编期刊
CNKI中文期刊全文数据库全文收录期刊
中国核心期刊(遴选)数据库全文收录期刊
万方数据——数字化期刊群收录期刊
中文科技期刊数据库全文收录期刊

主管:陕西省卫生健康委员会
主办:西安心身医学研究所
   西安交通大学第一附属医院
国际标准刊号:ISSN2096—1413
国内统一刊号:CN61—1503/R

不同剂量瑞舒伐他汀在急性冠脉综合征经皮冠状动脉介入治疗术后患者中的临床效果

杨鲲

(武警陕西省总队医院,陕西 西安,710054)

浏览次数:137次 下载次数:416次

摘要:

目的 探讨急性冠脉综合征患者经皮冠状动脉介入(PCI)治疗术后采用不同剂量瑞舒伐他汀治疗的临床效果。方法 将 2013 年1 月至2015 年1 月我院心血管内科收治的300 例行经皮冠状动脉介入治疗的急性冠脉综合征患者根据治疗方式不 同分为三组,每组100 例。A 组患者给予5 mg/d 瑞舒伐他汀治疗,B 组给予10 mg/d 瑞舒伐他汀治疗,C 组给予20 mg/d 瑞舒 伐他汀治疗。比较三组患者的临床效果。结果 治疗后,三组患者hs-CRP、BNP、TC、TG、HDL-C、LDL-C 水平均较治疗前明显 改善(P<0.05),C 组患者hs-CRP、BNP、TC、TG、LDL-C 水平明显优于A 组和B 组(P<0.05);三组患者不良反应发生率及心脑 血管事件发生率比较,差异无统计学意义(P>0.05)。结论 急性冠脉综合征患者介入治疗后采用高剂量瑞舒伐他汀治疗能有 效减轻患者的炎性反应,改善心功能和血脂水平,且不增加不良反应,安全性高,具有较高的临床应用价值。

关键词:急性冠脉综合征;瑞舒伐他汀;经皮冠状动脉介入治疗(PCI);不同剂量

中图分类号:R541.4文献标志码:A文章编号:2096-1413(2018)02-0017-03

    Clinical effects of different doses of rosuvastatin in patients with acute coronary syndrome after percutaneous coronary intervention
    YANG Kun
    (Armed Police Corps General Hospital of Shaanxi, Xi``an 710054, China)

    ABSTRACT: Objective To investigate the clinical effects of different doses of rosuvastatin in patients with acute coronary syndrome after percutaneous coronary intervention (PCI). Methods A total of 300 patients with acute coronary syndrome after PCI admitted in our hospital from January 2013 to January 2015 were selected and divided into three groups according to the treatment methods, with 100 cases in each group. Group A was given 5 mg/d rosuvastatin, group B was given 10 mg/d rosuvastatin, group C received 20 mg/d rosuvastatin. The clinical effects were compared among the three groups. Results After treatment, the levels of hs-CRP, BNP, TC, TG, HDL-C and LDL-C in the three groups were better than those before treatment (P<0.05), and hs-CRP, BNP, TC, TG LDL-C of the group C were better than those of the group A and group B (P<0.05). There were no significant differences in incidences of adverse reactions and cardiovascular events among the three groups (P>0.05). Conclusion High dose of rosuvastatin in patients with acute coronary syndrome after PCI can effectively reduce the inflammatory response of the patient , improve the cardiac function and the blood lipid level , does not increase the adverse reaction and has high safety, which has higher clinical application value .
    KEYWORDS: acute coronary syndrome; rosuvastatin; percutaneous coronary intervention (PCI); different doses

    参考文献:
    [1] 段霄燕,任晓兰,余建中,等.瑞舒伐他汀对急性冠状动脉综合征患 者介入后血管内皮功能、血清炎症因子和预后的影响[J].重庆医 学,2015,44(1):52-54.
    [2] 苏强,李浪,周游,等.负荷剂量瑞舒伐他汀对不稳定型心绞痛患者 PCI 术后炎症因子的影响[J].中国急救医学,2013,33(9):801-804.
    [3] 陈灏珠.实用内科学[M].12 版.北京:人民卫生出版社,2005:1472.
    [4] 王爱琴.瑞舒伐他汀与辛伐他汀对急性ST 段抬高型心肌梗死患者经皮冠状动脉介入治疗术后存活心肌功能及动脉粥样硬化的 影响[J].实用心脑肺血管病杂志,2014,22(6):23-24.
    [5] 宁小方,姬富才.瑞舒伐他汀对冠心病患者经皮冠状动脉介入治疗 术后血管内皮功能及预后的影响[J].中国基层医药,2016,23(24):3688-3691.
    [6] 李新峰,张领,李满生,等.不同剂量瑞舒伐他汀钙对经皮冠状动脉介入治疗术后预后的影响[J].中国临床实用医学,2015,6(6):30-32.
    [7] MACWAN JS,IONITA IA,DOSTALEK M,et al.Development and validation of a sensitive, simple, and rapid method for simultaneous quantitation of atorvastatin and its acid and lactone metabolites by liquid chromatography-tandem mass spectrometry (LC -MS/MS) [J]. Anal Bioanal Chem,2011,402(3):1217-1227.
    [8] ZHOU C,GAO W,LU G,et al.Preparation, characterization and in vitro release of microparticles based on dextran-rosuvastatin conjugate
    [J].Carbohydr Polym,2013,96(1):156-162.
    [9] GILROY EA,KLINCK JS,CAMPBELL SD,et al.Toxicity and bioconcentration of the pharmaceuticals moxifloxacin, rosuvastatin, and drospirenone to the unionid mussel Lampsilis siliquoidea[J].Sci Total Environ,2014,487(1):537-544.
    [10] 张兰芳,齐晓勇,贾新未,等.不同剂量瑞舒伐他汀对急性心肌梗死 经皮冠状动脉介入治疗患者心肌再灌注及心功能的影响[J].中 国临床药理学杂志,2015,31(13):1223-1226.

上一篇盐酸吗啡缓释片联合阿米替林对重度癌症疼痛伴抑郁患者的疗效

下一篇托伐普坦辅助治疗对急性心力衰竭患者的HR、SBP、 BNP 及24 h尿量的影响